Stocktoria
XBiotech Inc. XBIT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-15
XBiotech Inc. statistics & valuation
Market cap$71.7M
P / B0.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | 83.8% | 68.4% |
| Operating margin | — | — | — | -860.1% | -136.4% |
| Net margin | — | — | — | -820.4% | -94.7% |
| FCF margin | — | — | — | -384.3% | 358.4% |
| Return on assets | -30.3% | -19.4% | -10.8% | -13.4% | -6.3% |
| Return on equity | -32.4% | -21.1% | -11.2% | -13.7% | -6.5% |
| Current ratio | 16.01 | 11.56 | 33.07 | 54.07 | 71.49 |
| Revenue growth | — | — | -100.0% | -78.2% | -58.2% |
Source: SEC EDGAR filings · CIK 0001626878 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.